Senores Q1: consolidated PAT ₹30.5 Cr, EBITDA +87% YoY as margins expand ~800bps
PAT +43.8% YoY · revenue +36% · margins expanding · beat vs street
₹180.21 Cr
+36% YoY
₹30.45 Cr
+43.8% YoY
16.64%
+1.7pp YoY
₹6.61
Senores Pharmaceuticals opened FY27 with broad-based growth: consolidated revenue rose 36% YoY to ₹180.2 Cr (Q1FY26 ₹132.6 Cr) and net profit after tax climbed to ₹30.5 Cr from ₹21.2 Cr, +44% on the reported line and +56% on the ₹30.7 Cr attributable to owners — the figure the company headlines. The real story is profitability: EBITDA jumped 87% to ~₹54 Cr with roughly 800bps of margin expansion, lifting net margin to ~16.6% from ~15.0% a year ago. The lift was driven by the Regulated Markets segment (₹127.8 Cr, +42% YoY), where the ANDA portfolio nearly doubled to 58 approvals (30 a year ago, 23 commercialised), plus manufacturing/cost efficiency; Emerging Markets grew ~30% to ₹37.6 Cr but at a thinner ~14% EBITDA margin. Sequentially PAT is down ~17% versus Q4FY26's ₹36.7 Cr, but that quarter carried ₹17.7 Cr of other income and a deferred-tax benefit, so the QoQ optics understate the underlying trajectory.
Q1 FY-2027 vs prior quarters
Against management's own FY27 guidance — 30-40% revenue growth, 50-60% PAT growth, blended EBITDA margin 29-31% — Q1 tracks squarely inside the range (revenue +36%, EBITDA margin ~30%, owners' PAT +56%). Versus the street, Trendlyne's 4-analyst FY27 view models ~37.7% revenue growth but only ~27.9% profit growth, so the quarter's profit delivery runs ahead of consensus pace even if revenue is in line. Management (MD Swapnil Shah) framed it as a 'healthy performance despite a challenging environment,' flagging that the newly acquired Baroda-based USFDA-approved Apnar plant has already ramped production, that Emerging Markets is now cash-flow positive at near-mid-teens EBITDA margin, and that the US marketing/distribution JVs should scale the US business 'multifold.' Concurrent board actions this quarter: appointment of Anjali Shah as SMP (AVP-Finance), and a shareholder postal ballot to vary IPO-proceed usage — ₹100 Cr earmarked for the Atlanta sterile-injectables plant remains parked (only ₹6.98 Cr of ₹107 Cr deployed), the one open item on the capex plan. Standalone results (revenue ₹27 Cr, PAT ₹1.0 Cr) diverge sharply from consolidated and should not be read as the group picture — the US-heavy subsidiaries carry the business.
The stock went into the print at ₹1,401, up 10.3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Basic EPS ₹6.61 vs ₹4.60 YoY. Standalone far smaller (revenue ₹27 Cr, PAT ₹1.0 Cr) as the business sits in US/subsidiaries.
Management provides strong FY27 guidance with expected revenue growth of 30-40% and PAT growth of 50-60%, supported by a robust product pipeline and recent acquisitions. They anticipate maintaining a blended EBITDA margin of 29-31%. Key contributions are expected from the newly acquired Apnar facility (INR 80-100 Cr) a
— This quarter: met
W1
FY27 guidance checkpoint: revenue +30-40% / PAT +50-60% / EBITDA 29-31% — Q1 at +36% rev and ~30% EBITDA margin tracks; watch H2 delivery.
W2
Apnar (Baroda) scale-up over next 12-18 months (guided ₹80-100 Cr contribution) and Atlanta sterile-injectables capex — ₹100 Cr of ₹107 Cr IPO earmark still parked, only ₹6.98 Cr deployed.
W3
Emerging Markets EBITDA margin (~14% now) trajectory and the US government/federal-supply JV ramp.
Clean digital filing, limited-reviewed (unaudited), ₹ Crore. Consolidated Net Profit after tax ₹30.45 Cr; profit attributable to owners of parent ₹30.72 Cr (NCI −₹0.27 Cr) — company/media headline 'PAT ₹31 Cr, +56% YoY' uses the owners' figure, so YoY is +44% on total PAT vs +56% on owners' PAT. No exceptional items. Standalone is tiny (PAT ₹1.03 Cr, other income ₹9.55 Cr on ₹27 Cr revenue) as the bulk of operations sit in US/other subsidiaries. Prior quarter (Q4FY26) consol PAT ₹36.67 Cr was flattered by ₹17.67 Cr other income + a deferred-tax benefit, so QoQ PAT −17% is base-driven.
Pipeline boom, profit lags: execution risk surfaces
Revenue hit target at ₹180.2 Cr (+30.6% YoY), but PAT growth (43.8%) fell nearly 1,000 basis points short of the FY27 guidance floor (50–60%). Management reaffirmed full-year guidance anyway, setting up a binary Q2: either Q1 was the floor and accels happen now, or the annual target is at risk.
At first glance, Senores delivered on revenue: ₹180.2 Cr grew 30.6% year-over-year, right at the floor of its FY27 guidance band (30–40%). Profit, however, tells a different story. PAT of ₹30.4 Cr expanded 43.8% YoY — a respectable number on its own — but management had guided for 50–60% PAT growth for the full year. Missing that floor by nearly 1,000 basis points in the first quarter is not a small gap. On the call, management reaffirmed the full-year targets anyway. The market's reaction — down 6.24% on day 1, -8.47% by day 3, with no recovery — suggests investors are reading this as execution risk, not a conservative start.
What management said vs. what the numbers show
What changed on this call
Three strategic shifts surfaced on the earnings call, each significant for how capital and execution have been rebalanced since the prior quarter:
Sterile injectable greenfield delayed: ₹100 Cr capex plan scaled back to a pilot-only approach in H2 FY27, with capex redirected to oral solid expansion at Apnar and US facilities
Apnar facility ramping faster than initial plan: Acquired opportunistically (not part of original prospectus roadmap), now 80–90% utilized with 30M units/Q and 3rd/4th production lines underway
Branded generics repositioned from volume to profitability: Revenue flat-to-down QoQ but targeting ₹50–60 Cr with 35–40% EBITDA margin, a deliberate margin focus over volume chase
The capex reallocation is ROI-driven — Apnar's accelerated payback and oral solids momentum outpaced the original sterile injectable thesis — but it does represent a mid-stream pivot from the IPO prospectus. Management articulated the logic credibly; execution will prove whether the trade-off was right.
The pipeline and the execution gap
Here is where the bull case and the execution risk collide. Senores has built a structural advantage: 58 approved ANDAs (up from 30 in the prior 12 months), with 23 already commercialized and 35 queued for launch over the next 18–20 months. Additionally, its emerging markets portfolio spans 500 approved products and 900+ registrations in the pipeline, supported by PIC/S certification (completed for Chhatral in Q1, unlocking EU and other regulated markets in Q2–Q3). The ₹2,500–3,000 Cr multi-year revenue target (3–4 years out, a 13–17x expansion from ₹180 Cr) is quantified with concrete mechanisms: 58 ANDA launches, 900+ emerging market registrations, CDMO/CMO leverage, and branded generics ₹50–60 Cr.
The execution risk surfaces when you zoom in on Q1. Management launched 7 products this quarter; management's own words were that these launches were immaterial to top-line revenue. That is honest, but it also raises a question: if 7 launches contribute nil to revenue in the quarter they debut, how fast will 35 launches over 18 months convert to commercial scale? The answer matters because the PAT growth to 50–60% FY27 is dependent on these launches ramp, not just pipeline depth.
The bull case and the bear case
The honest read: This is not a fraud or a broken story. The pipeline is real, the regulatory milestones are real, and the multi-year target has a plausible roadmap. But Q1 proved that strategy and execution are not the same thing. The market's -6.24% day-1 and -8.47% day-3 move (with no recovery bounce) reflects Street skepticism on whether management can close the PAT growth gap in the remainder of the year. That skepticism is not unreasonable given a 1,000 basis-point miss in Q1.
Market positioning: price, valuation, and flows
₹1,305.70
as of Jul 31, 2026
-13.52%
from all-time high ₹1,509.80
+85.18%
from ₹705.10; RSI 29.5 (oversold)
-6.1%
₹1,390.21; below 20-day trend
above both
mid-term structure intact
Senores shares are deeply oversold on RSI (29.5, significantly below 30) and have unwound 13.5% from all-time high. However, the stock remains +85% above its 52-week low, and it sits above both the 50-day and 200-day moving averages — so the downtrend, while sharp, has not yet broken structural support.
The post-result price action is the critical tell. Announced on Monday Jul 27 at ₹1,412 (pre-result close), shares fell 6.24% on day 1 and 8.47% by day 3. Crucially, there was no recovery bounce. When a stock misses guidance and immediately rebounds, the market is forgiving a one-quarter stumble. When it gaps down and stays down, the market is repricing the risk outlook. That is what happened here.
Ownership has remained stable: FII 3.64% (QoQ +0.29 ppt), DII 9.61% (+0.3 ppt), promoter 45.82% (+0.02 ppt). No evidence of institutional panic-selling or insider stock liquidation. The move is pure valuation re-rating, not distribution.
Ranked risks: what should concern a holder
ANDA launch commercialization cadence
High35 approved ANDAs must launch and ramp to commercial scale over 18–20 months to hit ₹2,500–3,000 Cr multi-year target and generate 50–60% PAT growth in FY27. Q1 launched 7 products with nil revenue impact. If this trajectory persists, the full-year guidance and long-term roadmap both face downside.
PAT growth gap to FY27 target
HighQ1 at 43.8%, FY27 guidance 50–60%; need ~600 bps per quarter acceleration for remainder of year. If Q2 decelerates or stalls (< 15% QoQ growth), full-year miss is locked and guidance trim likely in Q2 call.
Emerging market EBITDA margin recovery
MediumH1 margin compressed 20%→14% QoQ; FY27 target 18–20% requires 6 ppt recovery in H2. Dependent on new product registrations materialize and PIC/S certification (Q2–Q3) unlocking regulated markets. Slippage here delays operating leverage.
Earnings communication quality
MediumPAT growth misstatement (56% vs. 43.8%) and revenue growth inflation (36% vs. 30.6%) are material 5–12 ppt gaps. Raises questions on management's internal controls and forecast accuracy for future quarters.
Capex reallocation from sterile injectables
LowGreenfield sterile plan scaled back mid-stream; now pilot-only. ROI-driven decision, but represents strategic pivot from IPO prospectus. Long-term sterile injectable contribution delayed, though unlikely to derail multi-year targets given emerging market and oral solids strength.
US tariff exposure (2028+)
LowPotential tariff on pharma imports in 2028; 2-year runway. Mitigated by Apnar facility (India) and US manufacturing presence, but margin compression risk if tariff rates exceed cost advantage. Contingent on India-US trade deal outcome.
What to watch next — the three things that resolve the debate
1 · Zoraya and Amerisyn operationalization (Sep–Oct 2026)
This is the first real test of go-to-market execution. These direct-to-patient (Zoraya) and government-contract (Amerisyn) channels launch in Sep–Oct. If these drive material incremental revenue in Q2 (the quarter after launch), confidence in the ANDA launch roadmap rises. If they are immaterial like Q1's 7 launches, the execution risk on 35 additional ANDAs is confirmed.
2 · Q2 PAT growth trajectory
This is the number that matters. If Q2 PAT grows > 15% QoQ sequentially, or shows acceleration toward 50–60% YoY, FY27 guidance becomes recoverable. If it stalls or decelerates (< 10% QoQ), the full-year 50–60% target is mathematically at risk and a guidance revision is likely in the Q2 earnings call.
3 · Emerging market EBITDA margin rebound in H2
Margin dipped 20%→14% QoQ in Q1 (attributed to H1 seasonality). Management guided 18–20% full-year. Confirmation of this recovery (via Q2–Q3 results and management commentary) or evidence of sustained margin pressure would reset long-term profitability expectations and impact the ₹2,500–3,000 Cr multi-year target credibility.
The verdict
Senores is not a broken story, but it is not executing as confidently as management's guidance implies. Revenue hit target, but PAT fell short by ~1,000 basis points in Q1. The strategy — a deep ANDA portfolio (58 approved, 35 queued), emerging markets at scale (900+ registrations pipeline), and capex-light CDMO leverage — is credible. But the first quarter's evidence is that converting approved drugs to commercial revenue takes longer than the quarterly cadence needed to hit full-year guidance.
The stock's -6.24% / -8.47% post-result decline (no bounce) is the market repricing execution risk, not panicking over a single quarter. An oversold RSI (29.5) and 13.5% drawdown from ATH suggest opportunity for a patient holder, but only if Q2 PAT accelerates and Sep–Oct launch ramps prove the execution gap is closing. A second quarter of PAT shortfall would confirm the full-year target is at risk.
The number to track from here: Q2 PAT growth. A return to 15%+ sequential growth (or material acceleration toward 50–60% YoY) resets confidence in the FY27 guidance. Continued deceleration or stall signals a guidance miss is locked, and share downside accelerates. This is a hold with a 60/40 execution skew — the strategy works, but the cadence is tighter than management originally signaled.
Pipeline boom, profit misses guidance floor
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit EBITDA margin target (30% within 29-31% guide). PAT growth missed floor—43.8% vs 50%+ FY27 target. Maintained guidance despite miss.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong ANDA pipeline (58 approved, 35 queued for launch) and margin stability (30% EBITDA) underpin a credible ₹2,500-3,000 Cr multi-year roadmap. However, Q1 PAT growth (43.8% YoY) missed FY27 guidance floor (50%), indicating execution risk. Emerging market margin compressed sequentially (20%→14%), requiring H2 recovery to hit 18-20% annual target.
₹180.2 Cr
Revenue · +30.6% YoY₹30.4 Cr
Reported PAT · +43.8% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
PAT grew 56% YoY, stood at ₹31 Cr
OVERSTATEDFiled result: PAT ₹30.4 Cr, grew 43.8% YoY
Consolidated revenue ₹180 Cr, 36% YoY growth
OVERSTATEDRevenue ₹180.2 Cr, actual YoY growth 30.6%
Regulated market grew 42% YoY
METTranscript notes actual growth is 42%, initially misspoke as 36%
EBITDA margin improved 810 bps to ~30%
METOPM 29.8%, implies EBITDA ~54 Cr (30% of 180)
Apnar ramped to 30M units, 6 products commercialized
METManagement stated 30M units, 18 products mapped, commercial revenue flowing
Earnings quality
What changed since the last call
Sterile injectable delayed, oral solids prioritized
DowngradeScaled down ₹100 Cr greenfield sterile plan; redirecting capex to expand oral capacity at Apnar and US. Now pilot-only approach for injectables.
Apnar facility scaled faster than expected
UpgradeAcquired opportunistically not planned; now at 80-90% utilization (30M units Q1), 3rd and 4th production lines underway vs initially unplanned capex.
Branded generics repositioned
NeutralShifted from volume (INR8→40 Cr YoY, 5x jump) to profitability; Q1 revenue -2% QoQ but margin focus 35-40%. Targeting INR50-60 Cr with 35-40% EBITDA.
FY27 guidance reaffirmed despite Q1 miss
NeutralRevenue 30-40%, PAT 50-60%, EBITDA margin 29-31% unchanged. Q1 PAT at 43.8% requires acceleration in Q2-Q4 to meet 50-60% target.
The Q&A
Analysts pressed hard on margin compression, sequential EBITDA/PAT declines, and ANDA launch execution risk. Management held firm, attributing sequential dips to seasonality and one-time F-Ex items; defended ANDA readiness with go-to-market finalized and manufacturing aligned. Defensive tone on sterile injectable deferral but credible on capex shift rationale.
Emerging market margin decline — Hrushikesh Vrajesh Shah, Alchemy Capital
AnsweredH1 is seasonally weak; last year Q1 was low single-digit %. Full year guidance 18-20% on track. Multiple new product registrations coming into effect this year will support margins.
Branded generics growth reversal — Hrushikesh Vrajesh Shah, Alchemy Capital
AnsweredGrew 5x YoY (INR8→40 Cr). Q1 focus shifted to profitability over volume; targeting INR50-60 Cr revenue with 35-40% EBITDA. Expect 30-40% YoY growth going forward.
ANDA portfolio expansion source — Sidharth Negandhi, CWC
PartialMix of acquisitions and organic development; strategy continues. Gross margin on sequential basis affected by product mix (regulated vs emerging). H1 weaker; expect improvement H2.
Sequential margin decline — Sidharth Negandhi, CWC
PartialH1 vs H2 seasonality in business. Q4 had ₹17 Cr other income; this quarter ~₹0. Even sequentially, grew for first time ever. Gross margin improved 1% QoQ.
ANDA launch commercialization — Sidharth Negandhi, CWC
Answered4-point go-to-market: Zoraya (own label), Amerisyn (government), B2B (out-license), CDMO/CMO. All 35 ANDAs have commercial partners mapped. Nothing sits unapproved without a strategy.
7 launches, muted revenue impact — Pranav Chawla, JM AMC
AnsweredLaunches this quarter were immaterial to top-line; more planned next quarter and Q4. Sticking to FY27 guidance; if revisions needed in couple quarters, will discuss.
IPO proceeds reallocation — Parth Sodha, Trinetra Asset Managers
AnsweredScaled down to prioritize oral solid capacity expansion at Apnar/US. Sterile moving to H2 this year as pilot. Change in object pending shareholder approval; decision based on better ROI.
Apnar commercialization and capex — Aanchal Maheshwari, Naredi Investment
Partial6 products commercialized from Apnar. 30M units produced Q1. 18 products mapped (launches + transfers from US). Expect 3-4 years to reach ₹2,500-3,000 Cr with similar/better margins.
Apnar utilization and expansion — Umesh Laddha, Ambit Capital
Answered80-90% utilization (much of this product qualification, not revenue). Capex FY27: ₹100-120 Cr across subs; major items are oral capacity and injectable pilot. Next year: ₹60-75 Cr minimum run-rate.
EU PIC/S opportunity size — Divyam Ketan Doshi, 9two3 Capital
DodgedToo premature to map revenue. Planning to file 100-120 products in EU over next year. Strong pipeline but revenue number not predictable yet.
NDA product strategy — Divyam Ketan Doshi, 9two3 Capital
DodgedOpportunities mapped and ongoing but too premature to comment. Excluded from 3-4 year guidance because approval paths unpredictable. Will be incremental upside if achieved.
US tariff impact on Apnar — Aniket Madhwani, Steptrade Capital
PartialWaiting for India-US trade agreement details. Already have US facility, so margin neutral. 2-year timeline too long to worry about; tariff scenarios change historically.
Guidance
FY27: +30-40% YoY revenue growth
HighGuided in prior calls; reaffirmed this call. Q1 at 30.6% suggests acceleration needed or lower end likely.
3-4 years: ₹2,500-3,000 Cr revenue
MediumQuantified target with roadmap: 58 ANDAs (23 live, 35 planned), 900+ emerging market registrations in pipeline, CDMO/CMO growth, branded generics ₹50-60 Cr.
FY27: EBITDA margin 29-31%
HighQ1 at 30% on track. Guided maintained despite emerging market H1 weakness; Q2-Q4 should recover.
FY27: maintain or improve 29-31% at 3-4 year ₹2,500-3,000 Cr revenue
MediumImplies margin expansion while scaling 13x revenue base; dependent on high-margin ANDA mix and CDMO leverage.
FY27: ₹100-120 Cr capex
HighOral solid capacity expansion (Apnar 3rd/4th lines, US), injectable pilot startup. No single facility-specific major capex.
FY28+: ₹60-75 Cr/year minimum run-rate
MediumMaintenance capex to sustain scaling; implies capital-intensive oral solids business model.
Risks the call surfaced
ANDA launch execution
High35 approved ANDAs planned for launch in 18-20 months. Q1 saw 7 launches contribute negligibly to revenue, raising risk that pipeline visibility isn't converting to timely commercial ramp.
Emerging market margin recovery
MediumH1 emerging market EBITDA margin fell 20%→14% QoQ. Full-year guidance 18-20% requires significant H2 recovery; dependent on new product registrations and price realization.
PAT growth target miss
MediumQ1 PAT growth 43.8% YoY; FY27 guidance 50-60%. Shortfall of ~600-1600 bps suggests Q2-Q4 must accelerate sharply or full-year target at risk. Management claims on-track but hedged.
Gross margin pressure
MediumSequential gross margin slight decline; management attributes to product mix (regulated vs emerging) and seasonality. Risk: if mix stays unfavorable, EBITDA target at risk despite top-line growth.
US tariff and trade policy
LowUS considering tariffs on generic pharma imports effective 2028. While Senores has US facility (Apnar) and US manufacturing, exposure depends on tariff scope and India-US trade deal specifics.
Management
Score 7/10. Transparent on pipeline roadmap and commercial strategy (4-point go-to-market articulated clearly). Candid on seasonality headwinds and IPO proceeds reallocation rationale. Withheld specifics on EU opportunity and NDA products (citing unpredictability), which is honest vs. speculative. ANDA portfolio doubled (30→58) in 12 months via mix of acquisitions and organic development. Apnar ramped to 30M units Q1, ahead of expectations. However, Q1 PAT growth (43.8%) missed FY27 guidance floor (50%), and ANDA launches immaterial to Q1 revenue, signaling execution challenges.
1 · Sep-Oct 2026
Zoraya (direct sales) and Amerisyn (government JV) operationalize; expect commercial ramp
2 · Q2-Q3 FY27
PIC/S certification for Chhatral facility; opens Vietnam, South Africa, Mexico markets
3 · Next 18-20 months
35 approved ANDAs planned for launch; strong visibility if execution on track
Emerging market margin compressed sequentially (20%→14%), requiring H2 recovery to hit 18-20% annual target.